We evaluated a double-antibody radioimmunoassay kit for thyrotropin that includes calibrators prepared in a matrix of human serum and involves overnight nonequilibrium. Results were compared with those from two reference assays for thyrotropin. The range of within-assay CV5 for the kit for thyrotropin values between 0.9 and 2.4 milli-int. units/L was 2.2 to 5.3%, that for between-assay CVs was 8.3 to 30%. The estimated minimum detectable concentration of thyrotropin was 0.6 milli-int. unit/L. We saw no cross reactivity with human choriogonadotropin by any of 48 sera from pregnant women. The original lot of serum specified as thyrotropin-free contained small but measurable amounts of thyrotropin; a second lot did not. Clinical data generated with the kit and the reference assays correlated well and were consistent with the clinical status of various categories of patients.
Materials and Methods
The two reference assays have previously been reported in detail (3, 4). Reference assay 1 (Al) (3) is a nonequilibrium assay in which human thyrotropin research standard "B" (68/38) (Medical Research Co#{241}ncil, Millhill, U.K.) is used. The antibody to human thyrotropin is used at a final dilution of l06-fold. The standards are in 200 L of thyrotropin-free human serum, and 200 L of unknown serum sample is used in the assay. All samples are run in duplicate. Standards and unknowns are incubated with antibody to thyrotropin for 48 h at 4#{176}C before the labeled thyrotropin tracer is added. The assay mixture is incubated for an additional 72 h, after which goat antibody to rabbit gammaglobulin is used to precipitate the bound fraction. After centriliigation, the supernate is aspirated and the radioactivity of the pellet containing the bound fraction is counted. For this assay we obtained thyrotropin-free serum from patients with thyroid cancer, thyroid nodules, or multinodular goiters, who were receiving thyroid hormone-suppression therapy and who in response to a 500-pg intravenous bolus injection of thyroliberin failed to demonstrate the presence of measurable thyrotropin in their serum (5) (6) (7) .
Reference assay 2 (A2) (4) is also a nonequilibnum assay. It differs from Al as follows: The volume of thyrotropin-free serum added to the standards and the volume of unknown samples are both 100 jzL. The initial incubation is for 60 hat 4#{176}C; the second incubation, after the thyrotropin tracer is added, is also 60 h. As with Al, the final dilution of antibody to thyrotropin is 106-fold. We used the nonequilibrium overnight protocol specified by the manufacturer (1) for the kit assay. Calibrators and unknown samples were run in duplicate, the thyrotropinfree serum supplied by the manufacturer being apportioned into calibrators in 200-FL volumes; the sample volume was also 200 L. The lyophilized rabbit antibody to thyrotropin was dissolved in 10 mL of distilled water (provided with the kit), and 100 zL was added to all tubes except the nonspecific-binding tubes. (The titer of the thyrotropin antibody in the final tube dilution is not specified by the manufacturer.) The contents of all tubes were vortex-mixed and incubated at room temperature for 18 h. The lyophilized lmI.labeled thyrotropin tracer was dissolved in 10 mL of distilled water, and 100 j.L of tracer (containing about 40 000 counts per minute) was added to all tubes, which were then vortexmixed and incubated at room temperature for another 5 h. To separate bound from free thyrotropin, we added to all tubes 2 mL of ice-cold precipitating solution, which consists of goat antibody to rabbit gamma-globulin and polyethylene glycol, 60 g/L, as supplied by the manufacturer. The contents of all tubes were vortex-mixed, incubated for a further for 20 mm at 1000 x g. The supernates were aspirated and discarded, and the radioactivity of the pellet, which contained the bound fraction, was counted for 1 mm. Two different lots of assay kits were evaluated: lot no. 061 in one laboratory, 063 in the other.
We estimated within-assay and between-assay CVs from the results of assaying six samples three times, in duplicate, on three separate occasions. For estimating the minimum and maximum reliably detectable thyrotropin concentrations, we used a four-parameter logistic program, adapted for use on the Hewlett-Packard Model 9830 computer (8). To the thyrotropin-free human serum used in Al and to the serum from the kit we added human choriogonadotropin (lot no. lOOF-0636; Sigma Chemical Co., St. Louis, MO 63178), to final concentrations of iO, 106, and l0 milli-int. unitsfL, to assess the cross reactivity of this hormone with the antibody to thyrotropin.
We compared the thyrotropin-fi-ee serum used in Al with the thyrotropin-free serum supplied with the kit. The manufacturer would not disclose the source or mode of preparation of their thyrotropin-free serum.
To assessthe kit's clinical performance, we studied seven groups of patients. (Table 1) CV for these same samples ranged between 8.3 and 30%.
Thyrotropin concentrations of 0.9 and 1.8 milli-int. unitWL gave between-assay CVs of 30 and 20%, respectively; for a concentration of 2.4 milli-int. unitsfL, the CV was 8. Conversely, thyrotropin-free serum used routinely in Al, when measured as an unknown in the kit, gave higher bound counts than the corresponding thyrotropin-free serum from the kit, showing an average B/B0 displacement of 104%. These results are consistent with the presence of small amounts of residual thyrotropin in the "thyrotropinfree" serum provided by the kit manufacturer.
In the various clinical groups the Al and the kit assays gave comparable mean values. Correlation coefficients calculated for normal subjects, pregnant patients, and patients with diminished thyroid reserve (as determined by Al) gave values of 0.56, 0.45, and 0.94, respectively.
The mean
thyrotropin values by Al tended to be slightly higher than those by the kit, which is consistent with the supposition that the human serum supplied with the kit was contaminated with small amounts of thyrotropin.
Although the data for the various groups of patients were appropriate to their clinical status, there was a pronounced tendency of thyrotropin values determined by A2 to exceed those by the kit (Table 1), particularly for samples from patients with primary hypothroidism and markedly increased thyrotropin concentrations. The correlation coefficients between results by the A2 and the kit assays for normal subjects, pregnant patients, and hypothyroid patients were 0.86, 0.95, and 0.60, respectively.
After we completed the kit evaluation, the manufacturer provided a second lot of thyrotropmn-free serum (no. HTD-3008) that, when assayed with Al, did not measurably displace lmIlabeled thyrotropin with respect to the thyrotropin-free serum used in Al.
Discussion
The well-recognized effect of whole human serum on tracer binding in radioimmunoassays for polypeptides is most pronounced in the low-dose region of the standard curve (4) and presents an important problem affecting the sensitivity limits for thyrotropin measurements by doubleantibody radioinununoassays (10). Use of dilute polyethylene glycol to accelerate the second-antibody reaction does not obviate the problem (11-13). Consequently, it is important to consistently account for this effect by incorporating into the calibrators of a thyrotropin immunoassay an appropriate amount of thyrotropin-free human serum so that the reaction mixture most closely matches the unknown samples (10) .
In the kit evaluated in this study a human serum matrix was used for the calibrators, and the clinical data obtained were comparable with those by the reference assays. However, the results emphasize the well-established fact that antibodies of different origin do not necessarily provide identical results across the broad range of analyte concentration encountered clinically (14). The clinical correlation between the results by the kit and those by Al in the limited clinical groups studied was closer than that between A2 results and the kit results. Some of this latter discrepancy might be attributable to a dilution of serum samples with the human serum supplied with the kit but, more probably, the magnitude of differences is simply intrinsic to two assays that involve different sample volumes and different antibodies to thyrotropin. Finally, our studies did not confirm the previously noted possibility of choriogonadotropin cross reactivity with thyrotropin (2). We conclude there is no need to adjust normal ranges or alter reportability of the assay for pregnant patients, at least for the lot of antibody to thyrotropin used in this study.
